WO2010150737A1 - コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料 - Google Patents

コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料 Download PDF

Info

Publication number
WO2010150737A1
WO2010150737A1 PCT/JP2010/060459 JP2010060459W WO2010150737A1 WO 2010150737 A1 WO2010150737 A1 WO 2010150737A1 JP 2010060459 W JP2010060459 W JP 2010060459W WO 2010150737 A1 WO2010150737 A1 WO 2010150737A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
degradation product
collagen production
collagen
axillary
Prior art date
Application number
PCT/JP2010/060459
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
和琴 武川
卓巳 渡邉
Original Assignee
コンビ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンビ株式会社 filed Critical コンビ株式会社
Priority to CN2010800282277A priority Critical patent/CN102458357A/zh
Publication of WO2010150737A1 publication Critical patent/WO2010150737A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a collagen production promoter comprising an axillary enzyme degradation product as an active ingredient. Specifically, the present invention relates to a collagen production promoter that promotes type I collagen production in dermal fibroblasts. Furthermore, the present invention relates to a composition for external use on skin and a cosmetic comprising an axillary enzyme degradation product as its active ingredient.
  • Skin troubles such as rough skin, wrinkles, sagging skin, and reduced tension are particularly important concerns for women. These skin problems are usually considered to be caused by environmental factors, factors associated with aging such as aging, and psychological factors such as stress. In particular, it can be said that environmental factors adversely affecting the skin due to the recent increase in ultraviolet rays and the drying of the living environment accompanying the frequent use of air conditioners are increasing.
  • Skin tissue consists of epidermis, dermis, and subcutaneous tissue.
  • the dermis contains a large amount of collagen and hyaluronic acid, and is greatly involved in the water retention and elasticity of the skin.
  • Collagen and hyaluronic acid are known to be produced by dermal fibroblasts present in the dermis.
  • Collagen is said to occupy about 30% of proteins existing in the human body, 70% of which exists in the dermis.
  • Collagen present in the dermis includes type I collagen and type III collagen, but the main one is type I collagen.
  • Reference 2 (Akiko Kojima-Yuasa, et al., Fragrance Journal, April, 2009, No. 346 (Vol.37, No. 4), pp.103-) suppresses the decrease in collagen production ability. This is useful for improving and improving QOL, and a decrease in the amount of collagen in the skin has been shown to cause wrinkles and sagging.
  • Axilla is a nest that swallows make by making their saliva into a thread, and it is known that it contains a lot of glycoprotein and almost no lipid.
  • Axilla is conventionally used as an edible material in Chinese cuisine, a raw material for Chinese medicine, and the like. In recent years, health foods using axilla as a raw material have been developed. However, only a few examples of application to external uses such as external preparations and cosmetics are known.
  • Japanese Patent Application Laid-Open No. 2003-95961 discloses an oral skin-beautifying agent using an axillary enzyme degradation product.
  • the effect here is to improve the moist feeling of the skin and to obtain a finely textured skin, which is related to the ability to promote the production of type I collagen, accompanied by improvement of skin tension and gloss, and improvement of wrinkles. Is not described at all.
  • WO99 / 022709 discloses a cosmetic containing an axillary hydrous solvent extract, particularly a hot water extract.
  • This cosmetic can be used for skin care and is used for external use.
  • the axillary water-containing extract exhibits an effect of promoting collagen synthesis in skin cells.
  • the extract used here is obtained by hot water extraction of the axilla to remove the solid content, which is clearly different from the axillary enzyme degradation product that is used as it is after the entire axilla is enzymatically treated. is there.
  • the effect as far as the present inventors considered, there was a room for improvement.
  • an axillary enzyme degradation product has an excellent production promoting effect of type I collagen in dermal fibroblasts. This effect was more prominent than the effect seen in the axillary hot water extract, and the effect was more prominent in the enzymatic degradation product that had been further enzymatically degraded.
  • the present invention is based on these findings.
  • an object of the present invention is to provide an excellent type I collagen production promoter that can be efficiently produced and highly safe, and an external preparation and a cosmetic containing the same.
  • the collagen production promoter according to the present invention comprises an axillary enzyme degradation product as an active ingredient.
  • the enzyme degradation product is a degradation product by protease.
  • the enzymatic degradation product has a molecular weight of 70 to 200,000.
  • the enzyme degradation product has an average molecular weight of 300 to 15,000.
  • the collagen production promoter according to the present invention is for promoting type I collagen production in skin dermal fibroblasts.
  • an external composition for skin comprising the collagen production promoter according to the present invention.
  • This composition is preferably used for skin care, more preferably for improving skin tension and gloss, and preventing or improving wrinkles.
  • the external composition for skin according to the present invention is a cosmetic.
  • an axillary enzymatic degradation product for producing a collagen production promoter in the skin of mammals including humans.
  • an axillary enzymatic degradation product for producing an external skin composition for skin care.
  • a method for promoting the production of collagen in the skin which comprises applying an effective amount of an enzyme degradation product as an active ingredient of the present invention to the skin of mammals including humans.
  • a skin care method comprising applying an effective amount of the active ingredient of the present invention to the skin of mammals including humans.
  • a method of improving skin tension and gloss and preventing or improving wrinkles comprising applying an effective amount of the active ingredient of the present invention to the skin of mammals including humans.
  • the production of collagen in human dermal fibroblasts can be significantly promoted as compared with the prior art.
  • the enzyme degradation product is used for external skin use or cosmetics, thereby improving skin tension (elasticity) and improving skin gloss.
  • wrinkles can be prevented or reduced.
  • collagen production can be promoted in skin in a state where collagen synthesis is lowered in the skin after tanning, thereby improving skin tension and gloss and improving wrinkles.
  • the enzyme degradation product used uses an axilla well-known as an edible material, it is highly safe and easily accepted by consumers. Furthermore, since the enzymatic degradation product can be obtained by subjecting the axilla directly to the enzyme treatment, it can be produced efficiently and the production cost can be kept low.
  • the collagen production promoter according to the present invention contains an axillary enzyme degradation product as an active ingredient.
  • the axilla which is the raw material of the enzyme degradation product, is a nest that swallows make by making their saliva into a thread, and it contains a lot of glycoprotein and almost no lipid.
  • the swiftlet is that swallows acids belonging to swiftlet genus (Collocalia) of swifts family (Apodidae), for example, Apodidae Collocalia francica, Apodidae Collocalia salangana , Apodidae Collocalia fuciphaga, Apodidae Collocalia inexpectata, Apodidae Collocalia vestita, Apodidae Collocalia Examples include esculenta and Apodidae Collocalia maximus .
  • a commercially available product can be used for the axilla.
  • axilla There are various types of commercially available axillas, ranging from those that have only been cleaned after removing dirt such as hair and feces, to those that have been collected by repeating bleaching and cleaning after collecting axilla debris.
  • the axilla used in the invention is preferably an axilla that has not been excessively washed or bleached in the pretreatment.
  • An axillary enzyme degradation product means a product obtained by degrading an axilla by applying an enzymatic reaction, and obtained by degrading an axilla or a processed product thereof using a protease, a complex enzyme containing a protease, or the like.
  • the enzyme used for the decomposition treatment is preferably a protease, more preferably pancreatin.
  • Axillary enzyme degradation products can usually be performed by first heat-sterilizing and then subjecting them to enzymatic treatment in water.
  • the conditions for the sterilization treatment can be set with reference to conventional heat sterilization conditions as appropriate, and the conditions for the enzyme treatment can also be set as appropriate according to the type of enzyme used and the state of the axilla.
  • an axillary enzymatic degradation product can be prepared as follows.
  • axillary processed product when the axillary processed product is enzymatically decomposed, 10 to 100 times the mass of water is added to an axilla ground to a particle size of 2 mm or less, preferably 150 ⁇ m or less, and 1 to 60 ° C., After leaving still for 0.5 to 48 hours or stirring to swell, heat sterilize at 60 to 130 ° C. for 5 seconds to 30 minutes, and filter as necessary. By subjecting to enzymatic treatment, an axillary enzymatic degradation product can be obtained.
  • an enzyme degradation product in which the enzyme reaction is further advanced by setting the enzyme reaction time to 0.5 to 48 hours, preferably 3 to 36 hours, more preferably about 24 hours is preferable.
  • the molecular weight of the axillary enzymatic degradation product thus obtained is preferably 70 to 200,000, more preferably 70 to 180,000. More preferably, the molecular weight is between 70 and 150,000, and even more preferably between 70 and 120,000.
  • the average molecular weight (weight average molecular weight) of the axillary enzyme degradation product is preferably 300 to 100,000, and more preferably 300 to 70,000. More preferably, the average molecular weight is 300 to 50,000, more preferably 300 to 30,000, still more preferably 300 to 20,000, and particularly preferably 300 to 15,000.
  • composition for external use of skin The collagen production promoter according to the present invention can be used alone as it is, but it can be added as an additive to various compositions for external use of skin such as cosmetics, pharmaceuticals and quasi drugs.
  • a composition having an effect of promoting collagen production can be obtained.
  • the obtained composition can be effectively used for skin care, preferably for improving skin tension and gloss and preventing or improving wrinkles.
  • the enzyme degradation product of axilla which is an active ingredient according to the present invention, has the activity of promoting the production of type I collagen in human dermal fibroblasts (test results of Examples described later).
  • the collagen production promoting activity means an action of promoting or improving the ability to produce type I collagen of fibroblasts of human skin dermis, thereby increasing the amount of collagen in human skin dermis. It means getting. It is well known to those skilled in the art that increasing the amount of collagen in the dermis can improve and prevent wrinkles, improve skin tension (elasticity), and improve skin gloss.
  • Non-patent Document 1 Experimental Method for Development of Functional Cosmetic Material
  • the active ingredient according to the present invention is suitable for skin care, preferably skin tension and gloss. Improvement and prevention or improvement of wrinkles It is clear that it is effective to.
  • prevention or improvement of skin or skin conditions such as skin tension, gloss, wrinkles, etc., adjustment, delay of progression, mitigation, prevention of onset, prevention of recurrence, suppression, etc. It is used in the meaning including.
  • an external composition for skin comprising the collagen production promoter according to the present invention.
  • the composition for external use on the skin is provided as a pharmaceutical, a quasi-drug, or a cosmetic, and more preferably as a cosmetic.
  • the content of the axillary enzyme degradation product as an active ingredient is not particularly limited and varies depending on the form of the composition. It is in the range of 0.001 to 20% by weight, preferably 0.005 to 5% by weight, and can be appropriately changed depending on the form of the composition.
  • the content of the axillary enzyme degradation product (in terms of dry matter) in the external composition for skin according to the present invention is 0.01 mg or more per day, more preferably 0.01 mg to 2 mg, so that it can be applied to the skin per square centimeter. It is preferable to include.
  • composition for external use of the skin according to the present invention contains an active ingredient, and the promoter according to the present invention may further contain other optional ingredients as long as the effect of promoting the production of collagen is not impaired.
  • optional components include various components commonly used in skin external preparations and cosmetics, such as humectants, lower alcohols, polyhydric alcohols, saccharides, surfactants, buffers, emulsifiers, and stabilizers.
  • Thickeners antioxidants, antiseptics, antiseptics, chelating agents, pH adjusters, fragrances, dyes, UV absorbers, UV scattering agents, vitamins, amino acids, anti-inflammatory agents, water, peptides, sugar alcohols , Enzymes, plant extracts, antioxidants, talc, clay, pollen, pearl and the like.
  • examples of the moisturizing agent include polyethylene glycol, polypropylene glycol, glycerin, propylene glycol, sorbitol, acidic mucopolysaccharides such as hyaluronic acid and chondroitin sulfate, amino acids, collagen, and elastin.
  • lower alcohols examples include ethanol, propanol, and isopropanol.
  • polyhydric alcohol examples include glycerin, pentaerythritol, dipentaerythritol, ethylene glycol, propylene glycol, polypropylene glycol, and 1,3-butylene glycol.
  • saccharide examples include saccharides such as glucose, maltose, lactose, D-glucuronic acid, saccharose, D-sorbitol, sorbitan, cellulose, and starch, oligosaccharides, polysaccharides, and derivatives thereof.
  • the composition for external use of the skin according to the present invention comprises a collagen production promoter containing an axillary enzyme degradation product and these optional components appropriately blended and adjusted in accordance with a known method, whereby a lotion, milky lotion, cream, moisturizing liquid, pack agent, It can be in the form of products commonly used in various cosmetics such as lotion, face wash, body lotion, body cream.
  • the external composition for skin according to the present invention further comprises makeup cosmetics such as foundations, lipsticks, eye shadows, blushers, medicinal cosmetics such as sunscreen products and deodorant cosmetics, and cosmetics for hair such as shampoos, hair rinses and hair conditioners. Further, it may be used as a skin cleanser or a bath cosmetic for a bath.
  • an axillary enzymatic degradation product for producing a collagen production promoter in the skin of mammals including humans.
  • the promotion of collagen production in the skin is preferably promotion of type I collagen production in skin dermal fibroblasts.
  • an axillary enzymatic degradation product for producing an external skin composition for skin care.
  • the external composition for skin is preferably used for improving skin tension and gloss and preventing or improving wrinkles.
  • the composition for external use on skin is preferably a cosmetic.
  • collagen in the skin comprising applying an effective amount of the enzyme degradation product which is the active ingredient of the present invention to the skin of mammals including humans.
  • the “effective amount” is an amount sufficient to exert collagen production promoting activity in a desired region in the body by application.
  • the promotion of collagen production in the skin is preferably promotion of type I collagen production in skin dermal fibroblasts.
  • a skin care method comprising applying an effective amount of the active ingredient of the present invention to the skin of mammals including humans.
  • a method of improving skin tension and gloss and preventing or improving wrinkles comprising applying an effective amount of the active ingredient of the present invention to the skin of mammals including humans.
  • the “effective amount” is an amount sufficient to obtain a desired effect.
  • the expression of a value using “about” and “degree” includes a variation in a value that can be allowed by those skilled in the art to achieve the purpose by setting the value. Meaning. For example, it means that a variation within 20%, preferably within 10%, more preferably within 5% of a predetermined value or range can be tolerated.
  • Axillary hot water extract (comparative example) 40 g of commercially available unbleached axilla (dried product) was pulverized with a pulverizer, and the pulverized product was added to 1000 ml of distilled water and subjected to extraction treatment under heating and reflux for 2 hours. After heating to reflux and allowing to stand, the supernatant was collected and filtered, and the filtrate was recovered. The residue was further added to 1000 ml of distilled water in the same manner as described above and subjected to a re-extraction treatment with heating under reflux, and then the solid residue was removed by filtration, and the filtrate was recovered. The obtained filtrate (extract) was combined and concentrated under reduced pressure, and the resulting concentrate was lyophilized to obtain a yellowish white “axillary hot water extract” (comparative example).
  • the amount of sialic acid and the amount of protein in each of the obtained axillary samples were measured as follows.
  • the amount of sialic acid was measured as free N-acetylneuraminic acid by high performance liquid chromatography after acid hydrolysis of each sample.
  • the amount of protein was measured using a Bio Rad protein assay kit based on the Brad ford method.
  • the molecular weight of the protein contained in the axillary enzyme degradation product was evaluated using the Western blot method. Specifically, first, according to the measurement method described above, the amount of protein in the axillary enzyme degradation product was confirmed. Proteins derived from axillary enzyme digest (100 ⁇ g) were separated by 10-15% polyacrylamide using SDS-PAGE. The protein developed on the gel was transferred to an Immuno-blot PVDF membrane (Polyvinylidene difluoride, obtained from Bio-Lad Lab). The PVDF membrane was blocked for 1 hour in PBS containing 3% skim milk and 0.1% Tween-20, and visually judged. In addition, in the evaluation of the molecular weight of the protein, data shown in known literature (Guo, CT, Suzuki Y., et al., Antiviral Res. 70, pp. 140-146 (2006) was also referred to.
  • the protein molecular weight contained in the axillary enzyme degradation product should be in the range of about 70 to 120,000 (the upper limit may be about 200,000 depending on the evaluation conditions). I understood.
  • the average molecular weight of the protein in the axillary enzyme degradation product 1 was about 55,000.
  • the average molecular weight of the protein in the axillary enzyme degradation product 2 was found to be about 33,000.
  • the culture supernatant was recovered, and the amount of type I collagen in the supernatant was measured by ELISA.
  • ELISA Anti-Human Collagen Type I antibody
  • Histofine PO Rabit
  • 2,2′-azinobis 3
  • the absorbance at 405 nm was measured with a microplate reader using (ethylbenzothiazoline-6-sulfonic acid) (ABTS).
  • ABTS ethylbenzothiazoline-6-sulfonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2010/060459 2009-06-23 2010-06-21 コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料 WO2010150737A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010800282277A CN102458357A (zh) 2009-06-23 2010-06-21 胶原产生促进剂、包含该胶原产生促进剂的皮肤外用组合物和化妆品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-148754 2009-06-23
JP2009148754A JP5815202B2 (ja) 2009-06-23 2009-06-23 コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料

Publications (1)

Publication Number Publication Date
WO2010150737A1 true WO2010150737A1 (ja) 2010-12-29

Family

ID=43386506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/060459 WO2010150737A1 (ja) 2009-06-23 2010-06-21 コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料

Country Status (5)

Country Link
JP (1) JP5815202B2 (zh)
KR (1) KR20120106703A (zh)
CN (2) CN107049907A (zh)
TW (1) TW201105362A (zh)
WO (1) WO2010150737A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5815203B2 (ja) * 2009-06-23 2015-11-17 コンビ株式会社 コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料
JP5914577B2 (ja) * 2014-06-09 2016-05-11 コンビ株式会社 コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料
JP5914576B2 (ja) * 2014-06-09 2016-05-11 コンビ株式会社 コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料
KR102204367B1 (ko) * 2014-07-16 2021-01-19 주식회사 엘지생활건강 피부 주름 개선용 화장료 조성물
JP7016117B2 (ja) 2016-01-18 2022-02-21 コスメディ製薬株式会社 コラーゲン化粧品
TWI636794B (zh) 2017-11-06 2018-10-01 吳治增 一種奈米複合材料及其應用
CN109771320A (zh) * 2018-12-24 2019-05-21 佛山科学技术学院 燕窝肽和植物精油复配的护肤品及其制备方法
CN109674731A (zh) * 2019-02-14 2019-04-26 厦门汇聚优品电子商务有限公司 一种含有鱼子精华的抗衰老组合物及其应用
WO2021167016A1 (ja) * 2020-02-18 2021-08-26 株式会社ファーマフーズ 卵黄膜および／またはカラザ由来の美容組成物、およびその製造方法
CN114762698A (zh) * 2021-06-16 2022-07-19 艾琳娜医疗管理(南京)有限公司 女性面部刺激胶原修复营养液及其设备方法
CN113876612B (zh) * 2021-11-12 2023-09-22 湖北省麦诗特生物科技有限公司 一种含有增加皮肤胶原密度脂质体的面霜组合物及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163110A (ja) * 1987-12-21 1989-06-27 Shiseido Co Ltd 皮膚老化予防剤
JPH06293788A (ja) * 1991-07-05 1994-10-21 Taiyo Kagaku Co Ltd 高純度シアル酸の精製法
JPH09301819A (ja) * 1996-05-09 1997-11-25 Nippon High Potsukusu:Kk 燕窩抽出物を含む化粧料
WO1999022709A1 (en) * 1997-11-05 1999-05-14 Nippon Hypox Laboratories Inc. Cosmetics and process for the preparation of extract of the nest of $i(oceanodroma sp.)
JP2003095961A (ja) * 2001-09-27 2003-04-03 Combi Corp 美肌促進剤
JP2005206547A (ja) * 2004-01-23 2005-08-04 Combi Corp ウイルス捕捉組成物、及びそれを吸着させたウイルス捕捉フィルター
WO2009008362A1 (ja) * 2007-07-12 2009-01-15 Yotsuba Milk Products Co., Ltd. シアル酸化合物含有組成物の製造方法
JP2009073806A (ja) * 2007-08-27 2009-04-09 Iriya Cosmetics Co Ltd インスリン様成長因子−１分泌促進剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3162224B2 (ja) * 1993-03-15 2001-04-25 日本碍子株式会社 シアル酸の調製法
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
CN100531708C (zh) * 2007-06-19 2009-08-26 浙江大学 一种化妆品用燕窝提取物的制备工艺
CN101606900B (zh) * 2008-06-17 2012-12-05 深圳绵俪日用化工有限公司 一种含燕窝提取液的净白美容面膜
JP5676077B2 (ja) * 2008-12-22 2015-02-25 コンビ株式会社 骨強度改善剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163110A (ja) * 1987-12-21 1989-06-27 Shiseido Co Ltd 皮膚老化予防剤
JPH06293788A (ja) * 1991-07-05 1994-10-21 Taiyo Kagaku Co Ltd 高純度シアル酸の精製法
JPH09301819A (ja) * 1996-05-09 1997-11-25 Nippon High Potsukusu:Kk 燕窩抽出物を含む化粧料
WO1999022709A1 (en) * 1997-11-05 1999-05-14 Nippon Hypox Laboratories Inc. Cosmetics and process for the preparation of extract of the nest of $i(oceanodroma sp.)
JP2003095961A (ja) * 2001-09-27 2003-04-03 Combi Corp 美肌促進剤
JP2005206547A (ja) * 2004-01-23 2005-08-04 Combi Corp ウイルス捕捉組成物、及びそれを吸着させたウイルス捕捉フィルター
WO2009008362A1 (ja) * 2007-07-12 2009-01-15 Yotsuba Milk Products Co., Ltd. シアル酸化合物含有組成物の製造方法
JP2009073806A (ja) * 2007-08-27 2009-04-09 Iriya Cosmetics Co Ltd インスリン様成長因子−１分泌促進剤

Also Published As

Publication number Publication date
JP2011006331A (ja) 2011-01-13
CN102458357A (zh) 2012-05-16
JP5815202B2 (ja) 2015-11-17
TWI559939B (zh) 2016-12-01
TW201105362A (en) 2011-02-16
KR20120106703A (ko) 2012-09-26
CN107049907A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
JP5815202B2 (ja) コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料
EP1433463B1 (en) Use of algal proteins in cosmetics
JP5588474B2 (ja) コラーゲンおよび／またはヒアルロン酸産生促進用組成物
JP4693623B2 (ja) 化粧料
JP5815203B2 (ja) コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料
KR20190014477A (ko) 은이 버섯 추출물, 이의 제조방법 및 이의 용도
JP2008110927A (ja) ローヤルゼリー蛋白加水分解物を含む化粧料
JP2004250372A (ja) 皮膚老化防止・改善剤及び／又は肌荒れ防止・改善剤キット
KR102139472B1 (ko) 기능성 펩타이드와 발효물을 포함하는 피부노화 개선용 조성물
WO2011115088A1 (ja) ヒト皮膚表皮細胞増殖促進剤、それを含む皮膚外用組成物および化粧料
KR101677460B1 (ko) 알레르기성이 감소된 수용성 로열젤리를 포함하는 피부 미백 및 노화방지용 화장료 조성물
JP5914576B2 (ja) コラーゲン産生促進剤、それを含む皮膚外用組成物および化粧料
JP5483928B2 (ja) 化粧料
JP5914577B2 (ja) コラーゲン産生低下抑制剤、それを含む皮膚外用組成物および化粧料
JP6704628B2 (ja) 化粧料
JP2004026766A (ja) 皮膚外用剤
KR101848647B1 (ko) 꼬막 추출물을 유효성분으로 포함하는 주름예방 또는 개선용 화장료 조성물
JP2009249366A (ja) コラーゲン産生促進剤、及び老化防止用皮膚外用剤
JP2022020422A (ja) 皮膚外用剤
JP2019210212A (ja) ヒアルロン酸産生促進剤、コラーゲン産生促進剤、ｍｍｐ阻害剤、シワ改善剤、医薬品又は食品組成物
JP2009215251A (ja) 抗炎症剤及び抗炎症用皮膚外用剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080028227.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792055

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127001655

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10792055

Country of ref document: EP

Kind code of ref document: A1